After Canaccord Genuity and William Blair gave Allogene Therapeutics (NASDAQ: ALLO) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Mark Breidenbach assigned a Buy rating to Allogene Therapeutics yesterday and set a price target of $50.00. The company’s shares closed last Wednesday at $30.98.
According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 9.8% and a 47.7% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Iovance Biotherapeutics, and Arvinas Holding Company.
Allogene Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $34.33, implying a 5.2% upside from current levels. In a report issued on April 29, Canaccord Genuity also maintained a Buy rating on the stock with a $36.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $35.61 and a one-year low of $17.43. Currently, Allogene Therapeutics has an average volume of 789.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
